Genentech Restricts Sales of Less Costly Agent for Macular Degeneration TreatmentOctober 12th 2007
SAN FRANCISCO -- Retinal specialists who use Genentech's bevacizumab (Avastin) off-label, instead of ranibizumab (Lucentis), to treat macular degeneration will soon find that their sources for the drug have dried up.
Willebrand's Disease or an Inherited Clotting FactorAugust 31st 2007
PRESTON, England -- From Addision's disease to Zollinger-Ellison syndrome, medical eponyms remain ubiquitous in the literature in favor of more scientific descriptions of disease. Now comes a proposal to do away with Down's and its ilk.
Disabled Child's Parents Defend Growth-Retarding TherapyJanuary 5th 2007
SEATTLE -- Parents of a severely cognitively and physically disabled girl have publicly defended their decision to retard her growth through the use of hormonal therapy and surgery, saying they were acting out of love and compassion.
Doctors Leave Levees and Lassitude BehindAugust 31st 2006
NEW ORLEANS -- For some physicians and nurses the decision to depart this city permanently is due to post-Katrina losses of practices, homes, and patients, but others cite discouragement and defeat at the failure of leadership that permeates the community.